ENSC
Ensysce Biosciences, Inc.NASDAQHealthcare$0.61-8.28%ClosedMarket Cap: $1.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.44
P/S
0.45
EV/EBITDA
854338.48
DCF Value
$156,551.31
FCF Yield
-554.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
-53.2%
Operating Margin
-321.6%
Net Margin
-319.5%
ROE
-375.0%
ROA
-136.5%
ROIC
-0.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-2.8M | $-2.8M | $-397,892.10 | — |
| FY 2025 | $0.00 | NaN% | $-10.24T | $-10.18T | $-397,895.97 | — |
| Q3 2025 | $493.1K | -499.2% | $-3.7M | $-3.7M | $-1.29 | — |
| Q2 2025 | $1.4M | -40.2% | $-1.8M | $-1.7M | $-0.79 | — |
| Q1 2025 | $1.3M | 100.0% | $-2.0M | $-1.9M | $-1.39 | — |
| Q4 2024 | $1.3M | -191.7% | $-3.6M | $-3.6M | $-2.90 | — |
| FY 2024 | $5.2M | -38.6% | $-6.7M | $-8.0M | $-4.57 | — |
| Q3 2024 | $3.4M | 50.5% | $644.7K | $661.8K | $0.35 | — |
| Q2 2024 | $181.8K | -421.0% | $-2.0M | $-2.0M | $-0.98 | — |
| Q1 2024 | $305.7K | -154.7% | $-1.8M | $-3.1M | $-1.46 | — |
| Q4 2023 | $515.0K | -333.5% | $-3.2M | $-3.5M | $-1.55 | — |
| FY 2023 | $2.2M | -240.1% | $-10.7M | $-10.6M | $-4.69 | — |